USFDA issues EIR with VAI classification to Solara Active Pharma Sciences’ Puducherry facility
The unannounced inspection was carried out by the US Food and Drug Administration between February 02, 2026 to February 6, 2026
US Food and Drug Administration (USFDA) has concluded inspection at Solara Active Pharma Sciences’ Ibuprofen manufacturing facility at Puducherry. USFDA has issued an EIR (Establishment Inspection Report) on April 24, 2026 with inspection classification of the facility as ‘Voluntary Action Indicated (VAI)’ and concluded this inspection as ‘Closed’.
The unannounced inspection was carried out by the US Food and Drug Administration between February 02, 2026 to February 6, 2026.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.
